Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


Our top-notch dedicated system is used to design specialised libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q9BYN8

UPID:
RT26_HUMAN

ALTERNATIVE NAMES:
28S ribosomal protein S13, mitochondrial; 28S ribosomal protein S26, mitochondrial

ALTERNATIVE UPACC:
Q9BYN8; Q96Q58

BACKGROUND:
Small ribosomal subunit protein mS26, known alternatively as 28S ribosomal protein S13 and S26, mitochondrial, is integral to mitochondrial protein synthesis. This protein is a key component of the mitochondrial ribosome, where it facilitates the translation of mitochondrial DNA-encoded proteins. These proteins are vital for mitochondrial function and, by extension, cellular energy metabolism, highlighting the protein's essential role in maintaining cellular health and function.

THERAPEUTIC SIGNIFICANCE:
Exploring the function of Small ribosomal subunit protein mS26 offers a promising avenue for developing novel therapeutic approaches. Given its central role in mitochondrial protein synthesis, targeting this protein could provide new strategies for managing conditions associated with mitochondrial impairments, thereby enhancing cellular energy production and overall health.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.